Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant PD-1 inhibitor + gemcitabine + cisplatin study in muscle-invasive bladder cancer
ChiCTR2000032757Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: pathologic complete response. Started May 2020; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2000032757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032757.